Comparative Pharmacology
Head-to-head clinical analysis: PARCOPA versus STALEVO 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PARCOPA versus STALEVO 50.
PARCOPA vs STALEVO 50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carbidopa inhibits decarboxylation of levodopa in the periphery, increasing levodopa availability to the brain. Levodopa is converted to dopamine in the CNS, replenishing dopamine levels in the striatum.
Stalevo 50 is a combination of carbidopa, levodopa, and entacapone. Levodopa is converted to dopamine in the brain, replenishing striatal dopamine levels. Carbidopa inhibits peripheral decarboxylation of levodopa, increasing its central availability. Entacapone is a selective, reversible inhibitor of catechol-O-methyltransferase (COMT), reducing peripheral metabolism of levodopa to 3-O-methyldopa, thereby prolonging its half-life.
0.5 mg orally three times daily, titrated slowly based on response and tolerability; maximum 8 mg/day.
One tablet (carbidopa 12.5 mg, levodopa 50 mg, entacapone 200 mg) orally, up to 8 tablets per day in divided doses, adjusting based on individual response. Maximum levodopa dose: 800 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-3 hours; in elderly patients, half-life may be prolonged due to reduced renal clearance, requiring dose adjustment.
Levodopa: 1-3 hours (short half-life necessitates frequent dosing; COMT inhibition by entacapone prolongs elimination half-life by ~1-2 hours vs levodopa alone). Carbidopa: 1-2 hours. Entacapone: 0.4-0.7 hours (terminal half-life in plasma).
Renal excretion of unchanged drug and metabolites accounts for approximately 60-70% of elimination; biliary/fecal excretion accounts for 20-30%.
Renal: ~80% (carbidopa: 70% unchanged, levodopa metabolites: 70-80% as HVA/DOPAC); Fecal: ~20% (entacapone: primarily as glucuronide conjugates via bile).
Category C
Category C
Anti-Parkinson Agent
Anti-Parkinson Agent